Lack of evidence for kynurenine pathway dysfunction in Huntington's disease: Cerebrospinal fluid and plasma analyses from the HDClarity study
We found no evidence to support the hypothesis of dysregulation of KP metabolites in HD based on CSF and plasma metabolite levels. The monitoring of KP metabolites in CSF or plasma is unlikely to serve as a pharmacodynamic biomarker for disease progression or therapeutic intervention in HD.
Authors
- Cristina Sampaio (ORCID: https://orcid.org/0000-0002-7052-9079)
- James Farnham
- Amber LaFayette
- Douglas R. Langbehn (ORCID: https://orcid.org/0000-0002-7803-4679)
- Edward J. Wild (ORCID: https://orcid.org/0000-0002-6921-7887)
- Robert E. Pacifici (ORCID: https://orcid.org/0000-0003-1465-362X)
- Vinod Khetarpal (ORCID: https://orcid.org/0000-0002-2175-5117)
- Ignacio Muñoz-Sanjuán (ORCID: https://orcid.org/0000-0003-0353-3577)
- Carmen Lozano Domínguez
- Bryan D. Marks
- Imran Rehmani
- Todd Herbst
- Aaron R. Ledvina
- Dennis Miller
- Hannah Anglehart
- Natasha Spridco
Institutions
- University of Iowa (US)
- LabCorp (United States) (US)
- CHDI Foundation (US)
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
Publication Details
- Journal
- Journal of Huntington s Disease
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1177/18796397241301761
- Citations
- 2
- Primary Topic
- Genetic Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.54
Funders
- CHDI Foundation
- University College London
- Medical Research Council